Vidac Pharma Holding Plc (ETR:T9G)

Market Cap	24.26M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	51.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4610
Previous Close	0.4600
Day's Range	0.4500 - 0.4710
52-Week Range	0.4500 - 0.9600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 30, 2026

About Vidac Pharma Holding

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors. The company...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2021
• Country: United Kingdom
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: T9G

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 28, 2026

Data Sources Report a data error